Celgene Corp (CELG)

CELG (NASDAQ:Drugs) EQUITY
$108.63
pos +2.40
+2.30%
Today's Range: 105.56 - 108.74 | CELG Avg Daily Volume: 4,209,000
Last Update: 07/27/16 - 3:31 PM EDT
Volume: 4,451,941
YTD Performance: -11.34%
Open: $106.02
Previous Close: $106.18
52 Week Range: $92.98 - $137.54
Oustanding Shares: 774,601,496
Market Cap: 83,602,739,463
6-Month Chart
TheStreet Ratings Grade for CELG
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 13 13 13
Moderate Buy 0 1 1 1
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.35 1.41 1.41 1.41
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 52.14
Price Earnings Comparisons:
CELG Sector Avg. S&P 500
52.14 52.30 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-1.27% -21.29% 47.53%
GROWTH 12 Mo 3 Yr CAGR
Revenue 20.70 0.70 0.19
Net Income -19.90 0.10 0.03
EPS -18.80 0.20 0.06
Earnings for CELG:
EBITDA 2.96B
Revenue 9.26B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $1.24 $1.30 $5.06 $6.31
Number of Analysts 3 3 3 3
High Estimate $1.26 $1.32 $5.11 $6.38
Low Estimate $1.20 $1.29 $5.00 $6.22
Prior Year $1.08 $1.12 $4.08 $5.06
Growth Rate (Year over Year) 14.51% 16.07% 23.94% 24.85%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
Continuing Oil Weakness. Crude is trading at $42.62 as I write this, down $0.71 this morning. U.S. Dollar Strength. The greenback's recent firmness is continuing this morning. A Flattening Yield Curve. A yield curve that's flattening out
Anheuser-Busch increases its offer for SABMiller after Brexit while the Federal Reserve prepares for action against Goldman Sachs.

Beware of False Profits Real Money Pro($)

"Beware of false prophets, who come to you in sheep's clothing but inwardly are ravenous wolves." -- Matthe
Chipotle, Wendy's on the bull side and gold stocks on the bear side.

I'm Bullish on Biotechs Real Money Pro($)

The market continues to trade lower as we late morning, with Tobira Therapeutics (TBRA) serving as the "disaster du jour" in the small-cap biotech space.
A look at who will be up and who will down this earnings season.
They need to do something that makes them stand out as stocks you want to own, not avoid.
Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.
From Celgene to Ford, these names look promising.
Biotech, restaurants and retail have been left for dead but are showing signs of life today.

Columnist Conversations

UPS will be reporting its 2nd quarter results before Friday's opening bell.  The stock has been fading si...
The FOMC essentially recycled the past couple of of policy statements at the conclusion of its two-day meeting...
we'll roll this to a higher strike, stock is breaking out. SOLD AGN SEP 250 CALL AT 14.40 (in at 9.30) B...
Ahead of the Fed announcement, my 4-hour momentum gauge suggests strongly that the S&P 500/ES is losing up...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.